OncoMatch/Clinical Trials/NCT07782632
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
Is NCT07782632 recruiting? Yes, currently enrolling (Sep 2026).
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy. The study explores whether baseline liver volume metrics can effectively predict survival outcomes and treatment responses in this patient population to assist in clinical decision-making.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Demographics
Prior therapy
Must have received: immunotherapy — tumor treatment regimen
Received immunotherapy as part of their tumor treatment regimen
Cannot have received: surgical resection for HCC
Prior surgical resection ... for HCC
Cannot have received: liver transplantation for HCC
Prior ... liver transplantation for HCC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07782632 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgical resection for HCC, liver transplantation for HCC disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages